Effect of obesity on dolutegravir exposure in Black Southern African adults living with HIV.

Mondleki, Enkosi; Banda, Clifford G; Chandiwana, Nomathemba C; Sokhela, Simiso; Wiesner, Lubbe; Venter, Francois; Maartens, Gary; Sinxadi, Phumla Z

Mondleki, Enkosi; Banda, Clifford G; Chandiwana, Nomathemba C; Sokhela, Simiso; Wiesner, Lubbe; Venter, Francois; Maartens, Gary; Sinxadi, Phumla Z.

Afiliação

Mondleki E; Division of Clinical Pharmacology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Banda CG; Division of Clinical Pharmacology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Chandiwana NC; Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi.
Sokhela S; Ezintsha, University of the Witwatersrand, Johannesburg, South Africa.
Wiesner L; Ezintsha, University of the Witwatersrand, Johannesburg, South Africa.
Venter F; Division of Clinical Pharmacology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Maartens G; Ezintsha, University of the Witwatersrand, Johannesburg, South Africa.
Sinxadi PZ; Division of Clinical Pharmacology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.

South Afr J HIV Med ; 23(1): 1452, 2022.

Article em En | MEDLINE | ID: mdl-36751628

Palavras-chave

HIV; South Africa; antiretroviral treatment optimisation; dolutegravir; obesity; pharmacokinetics

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Idioma: En Revista: South Afr J HIV Med Ano de publicação: 2022 Tipo de documento: Article País de afiliação: África do Sul

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google